Becton Dickinson (BDX)

Becton Dickinson (BDX-N) has undergone significant structural changes recently, including the spin-off of its life sciences business, which is now merged with WAT. This strategic shift positions BDX as a dedicated medical technology company, aiming to focus on higher-growth and higher-margin sectors. While the company's previous earnings per share (EPS) target for 2026 was $15, it has now adjusted this figure to $12.50. However, BDX's operating margin expectations have improved significantly, increasing from 21% to 25%. With the stock currently trading at a relatively cheap 14 times earnings, analysts remain cautious but optimistic, indicated by a price target of $200.00, describing the company as a wait-and-see opportunity due to the new risks associated with these changes.